Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Viking Holdings Ltd Ordinary Shares (VIK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Viking Holdings Ltd Ordinary Shares — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Viking Holdings Ltd Ordinary Shares trades at $82.22 (market cap $36.70B). The key difference: Viking Holdings Ltd Ordinary Shares is far larger — about 4.9× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Viking Holdings Ltd Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Viking Holdings Ltd Ordinary Shares for 6 Days on average.
| SYRE | VIK | |
|---|---|---|
Market Cap | $7.52B | $36.70B |
Volume | 1,441,031 | 2,076,556 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $108.26 |
52-Week Low | $22.18 | $57.08 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $6.52B | $39.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Viking Holdings (VIK) trades at $82.16, up 1.72% on the day, with a bullish technical signal and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue for 2025 reached $6.50 billion, with a net income margin of 19.33%, while analyst consensus is strongly bullish with an 86.66% buy rating and a $107.92 price target. Recent news highlights fleet expansion, a $1 billion share repurchase program, and premium positioning in luxury travel.
VIK presents a compelling growth opportunity driven by strong bookings, expanding fleet, and premium valuations, though risks include execution on capital expenditure and sensitivity to travel disruptions. The stock's current price near key support at $81 suggests potential for upward movement toward resistance levels, supported by positive institutional sentiment and operational cash flow strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Viking Holdings Ltd Ordinary Shares
Viking operates river, ocean, and expedition cruises. Its itineraries focus on destination-based travel across Europe, the Americas, and other regions.
Read more on VIK →
